Evidence map›Paper›PMID 35137335›Full record

ReviewCardiology and therapy2022

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.

Balbir Singh, Paresh Pai, Harish Kumar, Sheeba George, Sandeep Mahapatra, Vineet Garg, G N Gupta, Kiran Makineni, Gaurav Ganeshwala, Pravin Narkhede and 3 more

Abstract readReview
In one paragraph

Review in Cardiology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Evaluation of CHAJournal of clinical medicine · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Balbir SinghMax Super Speciality Hospital, Saket, New Delhi, India.
Paresh PaiLilavati Hospital and Research Centre, Mumbai, Maharashtra, India.
Harish KumarMoorthy Hospital Pvt. Ltd., Trichy, Tamil Nadu, India.
Sheeba GeorgeSree Mookambika Institute of Medical Sciences, Thiruvananthapuram, Kerala, India.
Sandeep MahapatraNizam's Institute of Medical Sciences, Hyderabad, India.
Vineet GargBlossoms Hospitals, Agra, Uttar Pradesh, India.
G N GuptaGupta Heart and Medical Centre, Gorakhpur, Uttar Pradesh, India.
Kiran MakineniKirans Vascular Surgery Centre, Vijayawada, Andhra Pradesh, India.
Gaurav GaneshwalaRuby Hall Clinic, Pune, Maharashtra, India.
Pravin NarkhedePVS Clinic, Nashik, Maharashtra, India.
Syed M H NaqviDr. Reddy's Laboratories Ltd., 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana, 500034, India.
Kumar GauravDr. Reddy's Laboratories Ltd., 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana, 500034, India. kumargaurav2@drreddys.com.
Mohammed Y K HukkeriDr. Reddy's Laboratories Ltd., 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana, 500034, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulation requires the integration of the correct type and dose of oral anticoagulants based on patient characteristic, and therefore therapy needs to be individualized for each patient. Growing scientific evidence from studies on NOACs has led to a better understanding of their benefits and safety. A large amount of available data creates a necessity for an adaptable practical document for the usage of NOACs in India. The current consensus, developed by experts from India, aims to give recommendations on various frequently raised clinical questions with regards to NOACs and its usage. This practical document provides a platform upon which future guidelines, policies, training, and education for the use of NOACs can be tailored.

Indexed as

AnticoagulantsApixabanAtrial fibrillationEdoxabanRivaroxabanVenous thromboembolism

Identifiers

PMID35137335
PMCPMC8933593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.